Recombinant production of peptide C-terminal α-amides using an engineered intein

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Recombinant production of peptide C-terminal α-amides using an engineered intein. / Albertsen, Louise; Shaw, Allan C; Norrild, Jens Chr.; Strømgaard, Kristian.

I: Bioconjugate Chemistry, Bind 24, Nr. 11, 20.11.2013, s. 1883-94.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Albertsen, L, Shaw, AC, Norrild, JC & Strømgaard, K 2013, 'Recombinant production of peptide C-terminal α-amides using an engineered intein', Bioconjugate Chemistry, bind 24, nr. 11, s. 1883-94. https://doi.org/10.1021/bc4002689

APA

Albertsen, L., Shaw, A. C., Norrild, J. C., & Strømgaard, K. (2013). Recombinant production of peptide C-terminal α-amides using an engineered intein. Bioconjugate Chemistry, 24(11), 1883-94. https://doi.org/10.1021/bc4002689

Vancouver

Albertsen L, Shaw AC, Norrild JC, Strømgaard K. Recombinant production of peptide C-terminal α-amides using an engineered intein. Bioconjugate Chemistry. 2013 nov. 20;24(11):1883-94. https://doi.org/10.1021/bc4002689

Author

Albertsen, Louise ; Shaw, Allan C ; Norrild, Jens Chr. ; Strømgaard, Kristian. / Recombinant production of peptide C-terminal α-amides using an engineered intein. I: Bioconjugate Chemistry. 2013 ; Bind 24, Nr. 11. s. 1883-94.

Bibtex

@article{dd02da16c2844921a32973206f3a31d9,
title = "Recombinant production of peptide C-terminal α-amides using an engineered intein",
abstract = "Peptides are of increasing interest as therapeutics in a wide range of diseases, including metabolic diseases such as diabetes and obesity. In the latter, peptide hormones such as peptide YY (PYY) and pancreatic peptide (PP) are important templates for drug design. Characteristic for these peptides is that they contain a C-terminal that is α-amidated, and this amidation is crucial for biological function. A challenge is to generate such peptides by recombinant means and particularly in a production scale. Here, we have examined an intein-mediated approach to generate a PYY derivative in a larger scale. Initially, we experienced challenges with hydrolysis of the intein fusion protein, which was reduced by a T3C mutation in the intein. Subsequently, we further engineered the intein to decrease the absolute size and improve the relative yield of the PYY derivative, which was achieved by substituting 54 residues of the 198 amino acid intein with an eight amino acid linker. The optimized intein construct was used to produce the PYY derivative under high cell density cultivation conditions, generating the peptide thioester precursor in good yields and subsequent amidation provided the target peptide.",
author = "Louise Albertsen and Shaw, {Allan C} and Norrild, {Jens Chr.} and Kristian Str{\o}mgaard",
year = "2013",
month = nov,
day = "20",
doi = "10.1021/bc4002689",
language = "English",
volume = "24",
pages = "1883--94",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",
number = "11",

}

RIS

TY - JOUR

T1 - Recombinant production of peptide C-terminal α-amides using an engineered intein

AU - Albertsen, Louise

AU - Shaw, Allan C

AU - Norrild, Jens Chr.

AU - Strømgaard, Kristian

PY - 2013/11/20

Y1 - 2013/11/20

N2 - Peptides are of increasing interest as therapeutics in a wide range of diseases, including metabolic diseases such as diabetes and obesity. In the latter, peptide hormones such as peptide YY (PYY) and pancreatic peptide (PP) are important templates for drug design. Characteristic for these peptides is that they contain a C-terminal that is α-amidated, and this amidation is crucial for biological function. A challenge is to generate such peptides by recombinant means and particularly in a production scale. Here, we have examined an intein-mediated approach to generate a PYY derivative in a larger scale. Initially, we experienced challenges with hydrolysis of the intein fusion protein, which was reduced by a T3C mutation in the intein. Subsequently, we further engineered the intein to decrease the absolute size and improve the relative yield of the PYY derivative, which was achieved by substituting 54 residues of the 198 amino acid intein with an eight amino acid linker. The optimized intein construct was used to produce the PYY derivative under high cell density cultivation conditions, generating the peptide thioester precursor in good yields and subsequent amidation provided the target peptide.

AB - Peptides are of increasing interest as therapeutics in a wide range of diseases, including metabolic diseases such as diabetes and obesity. In the latter, peptide hormones such as peptide YY (PYY) and pancreatic peptide (PP) are important templates for drug design. Characteristic for these peptides is that they contain a C-terminal that is α-amidated, and this amidation is crucial for biological function. A challenge is to generate such peptides by recombinant means and particularly in a production scale. Here, we have examined an intein-mediated approach to generate a PYY derivative in a larger scale. Initially, we experienced challenges with hydrolysis of the intein fusion protein, which was reduced by a T3C mutation in the intein. Subsequently, we further engineered the intein to decrease the absolute size and improve the relative yield of the PYY derivative, which was achieved by substituting 54 residues of the 198 amino acid intein with an eight amino acid linker. The optimized intein construct was used to produce the PYY derivative under high cell density cultivation conditions, generating the peptide thioester precursor in good yields and subsequent amidation provided the target peptide.

U2 - 10.1021/bc4002689

DO - 10.1021/bc4002689

M3 - Journal article

C2 - 24138202

VL - 24

SP - 1883

EP - 1894

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

IS - 11

ER -

ID: 96078077